MDXG
MiMedx GroupBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Composite grade B from latest DB weights. Momentum 35.3 / Value 70.0
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.4.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
35
Value
70
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $6.60
Why
Momentum35 · Δ7d +16.4
Value70 · Δ7d -0.4
SentimentN/A · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
35
40% active weight
Current posture
7d trendSoftening
Δ7d
+16.4
Δ21d
+7.4
Value
70
60% active weight
Current posture
7d trendFlat
Δ7d
-0.4
Δ21d
-0.5
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 35.3 / Value 70.0
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$640.47M
Beta
1.60
Shares Out
148.95M
P/E (TTM)
23.2
P/S (TTM)
2.38
P/FCF (TTM)
14.03
Rev YoY
-33.1%
EPS YoY
-256.1%
Gross Margin
+80.9%
Op Margin
+13.7%
Net Debt
-$143.59M
Current Ratio
5.39
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology